Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 5/20 | 0.42 |
| ▸ | TUBB | P07437 | 5/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661398 | 1.00 | TUBB4A (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24327468 | 0.87 | CDK9 (0.43) | NPC1RAB9ALRRK2CDK7CDK9 | |
| SCHEMBL29661342 | 0.87 | CDK9 (0.43) | NPC1RAB9ALRRK2CDK7CDK9 | |
| SCHEMBL24327587 | 0.86 | BRD4 (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29661472 | 0.86 | BRD4 (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24327315 | 0.85 | ZAP70 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29661317 | 0.85 | ZAP70 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29661413 | 0.85 | GLO1 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24328356 | 0.85 | GLO1 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29661334 | 0.85 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4382514-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-06-12 | — | — | EP | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | TUBB4A 2466/4885TUBB 1779/4885TUBA3C 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.